High FGL1 expression is associated with gefitinib resistance in non-small cell lung cancer (NSCLC), whereas low FGL1 expression is associated with sorafenib resistance in hepatocellular carcinoma (HCC), suggesting that FGL1 also plays significant roles in tumor therapy resistance11. Here, FGL1 is linked to neoplasm.